Streptogramin

TREATMENT

QuinupristinZdalfopristin (7.5 mg/kg IV q8h) is the only FDA-approved drug in the streptogramin class. This agent exerts its bacteriostatic effect by binding to the 50S bacterial ribosomal subunit, thereby inhibiting bacterial protein synthesis.

however, quinupristin/dalfopristin is inactive against E. faecalis.

SPECIAL CONSIDERATIONS

Adverse events include the possibility of severe arthralgias and myalgias, which occur frequently and can necessitate discontinuation of therapy. Injection site pain and thrombophlebitis are common. It has also been associated with elevated LFTs and requires dose adjustment in patients with hepatic impairment. Quinupristin/dalfopristin is similar to clarithromycin with regard to drug interactions.